MX2022002774A - Método de captura y purificación de productos biológicos. - Google Patents

Método de captura y purificación de productos biológicos.

Info

Publication number
MX2022002774A
MX2022002774A MX2022002774A MX2022002774A MX2022002774A MX 2022002774 A MX2022002774 A MX 2022002774A MX 2022002774 A MX2022002774 A MX 2022002774A MX 2022002774 A MX2022002774 A MX 2022002774A MX 2022002774 A MX2022002774 A MX 2022002774A
Authority
MX
Mexico
Prior art keywords
biologics
capturing
purification
methods
treatment
Prior art date
Application number
MX2022002774A
Other languages
English (en)
Inventor
Kumar Dhanasekharan
Christine Caroselli
Paul Langevin
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2022002774A publication Critical patent/MX2022002774A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/58—Reaction vessels connected in series or in parallel
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/02—Form or structure of the vessel
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M37/00—Means for sterilizing, maintaining sterile conditions or avoiding chemical or biological contamination
    • C12M37/02—Filters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Sustainable Development (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Clinical Laboratory Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen métodos para la producción continua, captura y purificación de productos biológicos tales como proteínas recombinantes. También se describen composiciones farmacéuticas que comprenden dichos productos biológicos, así como métodos de tratamiento y usos de dichos productos biológicos.
MX2022002774A 2019-09-06 2020-09-04 Método de captura y purificación de productos biológicos. MX2022002774A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962897018P 2019-09-06 2019-09-06
PCT/US2020/049535 WO2021046443A1 (en) 2019-09-06 2020-09-04 Method for capturing and purification of biologics

Publications (1)

Publication Number Publication Date
MX2022002774A true MX2022002774A (es) 2022-06-14

Family

ID=72562004

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002774A MX2022002774A (es) 2019-09-06 2020-09-04 Método de captura y purificación de productos biológicos.

Country Status (10)

Country Link
US (1) US20230220320A1 (es)
EP (1) EP4025242A1 (es)
JP (1) JP2022546587A (es)
KR (1) KR20220058587A (es)
CN (1) CN114341333A (es)
AU (1) AU2020343680A1 (es)
BR (1) BR112022004000A2 (es)
CA (1) CA3149955A1 (es)
MX (1) MX2022002774A (es)
WO (1) WO2021046443A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948653A (en) 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6244113B1 (en) 1999-10-29 2001-06-12 University Of Alabama In Huntsville Method and apparatus for measuring microgravity acceleration
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
EP2649016B1 (en) * 2010-12-06 2020-06-10 Pall Corporation Continuous processing methods for biological products
SI3201320T1 (sl) 2014-09-30 2024-02-29 Amicus Therapeutics, Inc. Zelo močna kislinska alfa-glukozidaza z okrepljenimi ogljikovimi hidrati
KR20230041833A (ko) 2015-12-30 2023-03-24 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
US10512676B2 (en) 2016-03-30 2019-12-24 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
KR20220145918A (ko) * 2016-03-30 2022-10-31 아미쿠스 세라퓨틱스, 인코포레이티드 고 m6p 재조합 단백질의 선택 방법
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Also Published As

Publication number Publication date
US20230220320A1 (en) 2023-07-13
CN114341333A (zh) 2022-04-12
BR112022004000A2 (pt) 2022-05-31
JP2022546587A (ja) 2022-11-04
WO2021046443A1 (en) 2021-03-11
AU2020343680A1 (en) 2022-03-24
EP4025242A1 (en) 2022-07-13
KR20220058587A (ko) 2022-05-09
CA3149955A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
MX2022014533A (es) Metodo para seleccionar proteinas recombinantes ricas en m6p.
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2021014286A (es) Proteinas multiespecificas.
MX2018011162A (es) Metodos de purificacion de colageno 7.
PH12018500379A1 (en) Biopharmaceutical compositions
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX2023014077A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
EP4219540A3 (en) Ctla-4 variant immunomodulatory proteins and uses thereof
MX2021000322A (es) Enzimas de variante fosfopentomutasa modificada geneticamente.
MX2021001129A (es) Metodo de purificacion de antigenos.
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
ECSP20083339A (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
WO2017123610A3 (en) Bacteria engineered to detoxify deleterious molecules
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
PH12020551618A1 (en) Erenumab compositions and uses thereof
MX2018009676A (es) Proceso.
MX2022000742A (es) Metodo para disminuir los efectos adversos del interferon.
MX2022002774A (es) Método de captura y purificación de productos biológicos.
IL284402A (en) A process for the production, isolation and purification of modified recombinant proteins
AU2014232502A8 (en) Process for the preparation of 4-amino-1-((1S,4R, 5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one